Longevity Protocol with Fatty Liver Disease

Why NAFLD Is a Longevity Emergency

Non-alcoholic fatty liver disease is routinely dismissed as a benign condition. This is dangerously wrong. NAFLD is the hepatic manifestation of systemic metabolic dysfunction — and the liver is the central metabolic organ. When the liver accumulates fat, it becomes insulin resistant, increases VLDL and triglyceride production, drives systemic inflammation, and impairs detoxification, hormone metabolism, and dozens of other critical functions.

The leading cause of death in NAFLD is not liver failure — it's cardiovascular disease. NAFLD independently doubles cardiovascular risk. It accelerates atherosclerosis, promotes atherogenic dyslipidemia (high triglycerides, low HDL, elevated small dense LDL and ApoB), and drives chronic inflammation that damages every organ system.

The progression cascade matters: simple steatosis (fat accumulation) → NASH (inflammation + fat) → fibrosis (scarring) → cirrhosis → liver failure or hepatocellular carcinoma. Only about 20% of NAFLD progresses to NASH, but given the prevalence (25-30% of all adults), the absolute numbers are staggering. NAFLD is projected to become the leading indication for liver transplantation.

The critical longevity insight: NAFLD is reversible at every stage before cirrhosis. Lifestyle intervention can reduce hepatic fat by 40-80% and even reverse fibrosis. The window for intervention is wide — but it requires aggressive action.

Exercise: The Liver's Best Medicine

Exercise reduces liver fat independently of weight loss — this is a critical point. Even without scale change, regular exercise reduces hepatic steatosis by improving hepatic insulin sensitivity, increasing fatty acid oxidation, and reducing de novo lipogenesis. Both aerobic and resistance training are effective.

Zone 2 cardio (150-300 min/week) — The strongest evidence for liver fat reduction. Moderate-intensity exercise that prioritizes fat oxidation. Walking, cycling, or swimming at conversational pace. More volume is better for NAFLD — aim for the upper end of the range.

Resistance training (2-3x/week) — Reduces liver fat even without aerobic training, likely through improved whole-body insulin sensitivity and increased metabolic rate. Particularly important because NAFLD is associated with sarcopenia (muscle loss), and muscle is the primary site of glucose and lipid disposal.

Reduce sedentary time. Independent of exercise, prolonged sitting increases hepatic fat accumulation. Break up sitting with 2-3 minute movement breaks every 30-60 minutes. Standing desks, walking meetings, and post-meal walks all contribute.

Nutrition: Reversing the Metabolic Driver

Eliminate sugar-sweetened beverages. This single change has the highest impact per effort of any dietary intervention for NAFLD. Fructose is metabolized almost exclusively by the liver and is the most potent dietary driver of hepatic de novo lipogenesis. Juice, soda, sweetened coffee drinks, and sports drinks are all problematic.

Mediterranean diet — The dietary pattern with the strongest evidence for NAFLD reversal. Olive oil, fatty fish, vegetables, legumes, nuts, and moderate wine intake. The PREDIMED trial subgroup analysis showed significant hepatic fat reduction with Mediterranean diet adherence.

Adequate protein (1.2-1.6g/kg/day) — Supports muscle preservation during weight loss, improves satiety, and has minimal contribution to hepatic fat. Distribute across meals. Coffee (3-4 cups/day, unsweetened) is independently associated with reduced liver fibrosis risk.

Weight loss of 5-10% — If overweight, losing 5% of body weight reduces hepatic fat by ~40%. Losing 10% can resolve NASH. The method matters less than the result — sustainable caloric deficit through any evidence-based approach works.

Time-restricted eating (14-16h overnight fast) — Allows hepatic glycogen depletion and shifts the liver toward fat oxidation. Multiple studies show TRE reduces hepatic fat independent of total caloric intake. Start with a 12-hour fast and extend gradually.

Testing Beyond Standard Liver Enzymes

ALT and AST are insensitive. Normal liver enzymes do not rule out NAFLD. Up to 80% of people with hepatic steatosis have normal ALT. However, the longevity-optimal ALT is lower than the lab range suggests: under 25 U/L for men, under 20 U/L for women. Track GGT as well — it's a more sensitive marker of hepatic metabolic stress.

Liver ultrasound — First-line imaging for NAFLD detection. Widely available and inexpensive. Detects moderate-severe steatosis but may miss mild disease.

FibroScan (transient elastography) — Quantifies both hepatic fat (CAP score) and fibrosis (kPa). Non-invasive, takes 10 minutes. The best available monitoring tool for NAFLD progression/regression. Repeat every 6-12 months if NAFLD is confirmed.

Metabolic panel — Fasting insulin, HOMA-IR, ApoB, triglycerides, hs-CRP. NAFLD is a metabolic disease — track the metabolic markers that drive it and the cardiovascular risk it amplifies.

FIB-4 score — A simple calculation from age, ALT, AST, and platelets that screens for advanced fibrosis. FIB-4 under 1.3 effectively rules out advanced fibrosis. Available online — calculate yours.

Supplements and Medications for NAFLD

Vitamin E (800 IU/day of d-alpha-tocopherol) — The PIVENS trial showed vitamin E improved NASH histology, including inflammation and steatosis, in non-diabetic patients. The most evidence-supported supplement for NAFLD. Use the natural d-alpha form, not synthetic dl-alpha.

Omega-3 fatty acids (2-4g EPA+DHA/day) — Reduces hepatic triglyceride content, lowers systemic triglycerides, and has anti-inflammatory effects in the liver. Particularly important given NAFLD's cardiovascular risk amplification.

Berberine (500mg 2-3x/day) — Activates AMPK in hepatocytes, reduces hepatic lipogenesis, and improves insulin sensitivity. Meta-analyses show significant reductions in hepatic fat and liver enzymes. Consider if not on metformin.

Resmetirom (Rezdiffra) — The first FDA-approved medication specifically for NASH with moderate-to-advanced fibrosis. A thyroid hormone receptor beta agonist that directly reduces hepatic fat. Represents a paradigm shift in NAFLD treatment.

GLP-1 agonists (semaglutide) — The LEAN, LIRA-NAFLD, and semaglutide NASH trials show dramatic hepatic fat reduction and even NASH resolution. Increasingly used off-label for NAFLD, especially with concurrent obesity or diabetes.

Coffee (3-4 cups/day) — One of the most consistently supported hepatoprotective interventions. Reduces fibrosis risk, lowers liver enzymes, and is associated with reduced hepatocellular carcinoma risk. The effect appears to be from coffee compounds beyond caffeine (kahweol, cafestol). Drink unsweetened.